CompletedPhase 4

Role of IV Calcium to Prevent Diltiazem-related Hypotension

Turkey (Türkiye)217 participantsStarted 2023-01-01

Plain-language summary

The objective of this study is to examine the efficacy and safety of IV calcium pretreatment at varying doses prior to weight-adjusted IV Diltiazem on the incidence of Diltiazem-related hypotension in adult patients presenting to the Emergency Department due to Atrial Fibrillation with Rapid Ventricular Response. Specifically, we tested the hypothesis that patients with Atrial Fibrillation who receive IV calcium pretreatment prior to IV Diltiazem suffer less hypotension than those receiving Diltiazem monotherapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged ≥ 18 years * Patients with documented AFib/AFL (confirmed by ECG) * Patients with a Heart Rate of ≥ 120 bpm, and a Systolic Blood Pressure of ≥ 90 mmHg Exclusion Criteria: * Patients under 18 years of age * pregnant individuals * Patients with hemodynamic instability requiring electrocardioversion * Patients with a documented history of sick sinus syndrome, third-degree AV block, Wolff-Parkinson-White syndrome * Patients with hypotension (SBP \<90 mmHg) * Patients with known or suspected hypercalcemia * Patients with a confirmed allergy to diltiazem * Patients with concurrent use of another Heart Rate control agent (such as beta-blockers, amiodarone, or digoxin) on the same admission

What they're measuring

Change in Systolic blood pressure before and after treatment

Timeframe: 5, 10, and 15 minutes following the initial administration.

Trial details

NCT IDNCT06494007

SponsorHaseki Training and Research Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-01

View on ClinicalTrials.gov More Atrial Fibrillation trials